GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Harnessing advanced data analysis for early detection, prevention and better outcomes
Subscribe To Our Newsletter & Stay Updated
